research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
Search
for
Sort by
Research
840-870 / 1000+ resultsresearch TRIAMCINOLONE ACETONIDE INTRAMUSCULARLY: EFFECTIVE LONG‐ACTING STEROID THERAPY IN DERMATOLOGIC DISORDERS
Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.
research The Efficacy of Intralesional Pentoxifylline Injection versus the Standard Intralesional Corticosteroid Injection in The Treatment of Alopecia Areata
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.
research 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
research Development, Optimization, and In Vitro/In Vivo Evaluation of Azelaic Acid Transethosomal Gel for Antidermatophyte Activity
Azelaic acid in a special gel is more effective against skin fungi than regular azelaic acid.
research Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Side effects of methotrexate therapy in patients with rheumatoid arthritis
Methotrexate is effective for rheumatoid arthritis but often causes side effects like nausea and liver issues.
research Cutaneous Adverse Events in Patients with Chronic Hepatitis C during Treatment with Directly Acting Antiviral Agents: A cohort study
34% of patients on hepatitis C treatment had reversible skin issues.
research Zolpidem-Associated Dermatitis Artefacta—An Unusual Cause of Cicatricial Alopecia
Stopping zolpidem improved hair loss caused by self-inflicted scalp injuries during sleep.
research Optimal laboratory testing protocol for patients with acne taking oral isotretinoin
Test liver enzymes and triglycerides every 5-6 months, and cholesterol levels in the first two months for acne patients on isotretinoin.
research Induction and reversal of pulmonary lipid histiocytosis in rats following oral administration of anorectics cloforex and chlorphentermine
Rats developed lung issues from the drugs, but these cleared quickly after stopping them.
research Intralesional Triamcinolone Acetonide in the Management of Acne Keloidalis Nuchae
Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
research Management of Recurrent Ischemic Priapism 2014: A Complex Condition with Devastating Consequences
Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.
research The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research Adverse Cutaneous Reactions to Antipsychotics
Some patients taking antipsychotic medications experience skin reactions, ranging from mild to severe.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
Baricitinib works better than methotrexate for severe alopecia areata.
research Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.
Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research Ziziphus: A prospective multi application fruit tree
Ziziphus is a versatile plant with health benefits and commercial uses.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients
Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.
research New-onset Majocchi’s granuloma in two kidney transplant recipients under tacrolimus treatment
Majocchi's granuloma can occur in kidney transplant patients on tacrolimus and can be treated with antifungal medication.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research G42 Long term safety and efficacy of single dose parenteral iron in children with inflammatory bowel disease in a large tertiary centre
Single-dose parenteral iron is safe and effective for children with inflammatory bowel disease and iron-deficiency anemia.
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Oral ivermectin in the treatment of scabies
Oral ivermectin effectively cured scabies with minimal side effects, and finasteride promoted hair growth in men with hair loss.
research THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.